AU4958199A - Hypericin and (hypericum) extract: specific t-type calcium channel blocker, and their use as t-type calcium channel targeted therapeutics - Google Patents

Hypericin and (hypericum) extract: specific t-type calcium channel blocker, and their use as t-type calcium channel targeted therapeutics Download PDF

Info

Publication number
AU4958199A
AU4958199A AU49581/99A AU4958199A AU4958199A AU 4958199 A AU4958199 A AU 4958199A AU 49581/99 A AU49581/99 A AU 49581/99A AU 4958199 A AU4958199 A AU 4958199A AU 4958199 A AU4958199 A AU 4958199A
Authority
AU
Australia
Prior art keywords
ocor
hypericin
hypericum
0cor
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU49581/99A
Other languages
English (en)
Inventor
Lei Ling
Peter K.T. Pang
Jacqueline J. Shan
Xi-Chen Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Afexa Life Sciences Inc
Original Assignee
CV Technologies Inc
CV Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Technologies Inc, CV Technology Inc filed Critical CV Technologies Inc
Publication of AU4958199A publication Critical patent/AU4958199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/95—Esters of quinone carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/36—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/54—Ortho- or ortho- and peri-condensed systems containing more than five condensed rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU49581/99A 1998-07-09 1999-07-09 Hypericin and (hypericum) extract: specific t-type calcium channel blocker, and their use as t-type calcium channel targeted therapeutics Abandoned AU4958199A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9222798P 1998-07-09 1998-07-09
US60092227 1998-07-09
PCT/US1999/014132 WO2000002455A1 (en) 1998-07-09 1999-07-09 Hypericin and hypericum extract: specific t-type calcium channel blocker, and their use as t-type calcium channel targeted therapeutics

Publications (1)

Publication Number Publication Date
AU4958199A true AU4958199A (en) 2000-02-01

Family

ID=22232251

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49581/99A Abandoned AU4958199A (en) 1998-07-09 1999-07-09 Hypericin and (hypericum) extract: specific t-type calcium channel blocker, and their use as t-type calcium channel targeted therapeutics

Country Status (7)

Country Link
EP (1) EP1094712A4 (de)
JP (1) JP2002520260A (de)
KR (1) KR20010071822A (de)
CN (1) CN1308492A (de)
AU (1) AU4958199A (de)
CA (1) CA2336781C (de)
WO (1) WO2000002455A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2351947C (en) * 1998-11-25 2008-10-21 Universitatsklinikum Freiburg Hyperforin as cytostatic agent and hyperforin ointment or cream as application form
AU3744100A (en) * 1999-03-15 2000-10-04 Shaman Pharmaceuticals, Inc. Bicyclo(3.3.1)nonenes useful for the treatment of diabetes
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
CN100534420C (zh) * 2001-09-25 2009-09-02 北京北大维信生物科技有限公司 一种治疗抑郁症的口服药
DE10213571A1 (de) * 2002-03-26 2003-10-23 Lichtwer Pharma Ag Pflanzenextrakte und deren Anwendung
KR100873400B1 (ko) * 2002-10-17 2008-12-11 한국과학기술연구원 Ｎ-타입 칼슘 채널의 활성을 억제함으로써 우울증을감소시키는 방법
AU2003277418A1 (en) * 2002-10-17 2004-05-04 Merck And Co., Inc. Enhancement of sleep with t-type calcium channel antagonists
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
US7157461B2 (en) 2003-07-23 2007-01-02 Bristol-Myers Squibb Co. Substituted dihydropyrimidine inhibitors of calcium channel function
US7504431B2 (en) 2004-04-16 2009-03-17 Bristol-Myers Squibb Company Sulfonyl amide inhibitors of calcium channel function
US20100048728A1 (en) * 2006-08-03 2010-02-25 Hy Biopharma Inc. Polycyclic dianthraquinones as inhibitors of inflammatory cytokines
WO2009108798A1 (en) 2008-02-29 2009-09-03 Vm Discovery Inc. Method for treating pain syndrome and other disorders
CN103285072B (zh) * 2012-02-24 2015-09-09 北京北大维信生物科技有限公司 包含金丝桃苷的提取物及其医药用途
CN103751303A (zh) * 2014-01-18 2014-04-30 史克勇 复方中药
EP3423428B1 (de) * 2016-03-01 2024-07-24 Soligenix, Inc. Systeme und verfahren zur herstellung von synthetischem hypericin
CN108084065B (zh) * 2017-11-21 2020-06-16 中国农业科学院兰州畜牧与兽药研究所 一种金丝桃素衍生物及其制备方法和应用
EP3725761B1 (de) * 2017-12-07 2024-01-03 Jiangsu Kanion Pharmaceutical Co., Ltd. Emodin-succinyl-ester-verbindung, herstellungsverfahren dafür und verwendung davon
CN110025604A (zh) * 2019-04-11 2019-07-19 中国科学院西北高原生物研究所 金丝桃素在制备抑制葡萄糖苷酶活性的相关产品中的用途
WO2024043242A1 (ja) * 2022-08-23 2024-02-29 国立大学法人九州大学 Ｔｒｐｃ３／６／７チャネル活性化による強心作用を介した心不全治療

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE108064T1 (de) * 1987-10-08 1994-07-15 Andor Bilas Stoffgemisch zur stabilisierung der stoffwechsel- lage.
US5288485A (en) * 1989-08-31 1994-02-22 Kao Corporation Vasodilating agent
IL92315A (en) * 1989-11-15 1996-12-05 Yeda Res & Dev Preparation of Hypericin from Amodin Enron
US5514714A (en) * 1990-08-23 1996-05-07 New York University Methods and polycyclic aromatic compound containing compositions for treating T-cell-mediated diseases
US6576784B1 (en) * 1993-05-27 2003-06-10 Yeda Research And Development Co. Ltd. Antiviral agents
WO1996030012A1 (en) * 1995-03-24 1996-10-03 Defeudis Francis V Methods for treating conditions associated with excess nitric oxide
AU5474198A (en) * 1996-12-24 1998-07-17 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
DE19700788A1 (de) * 1997-01-11 1998-07-16 Michael O Ruepp Johanniskraut-Trockenextrakte

Also Published As

Publication number Publication date
CA2336781C (en) 2010-12-14
EP1094712A4 (de) 2004-09-08
KR20010071822A (ko) 2001-07-31
EP1094712A1 (de) 2001-05-02
WO2000002455A1 (en) 2000-01-20
CA2336781A1 (en) 2000-01-20
CN1308492A (zh) 2001-08-15
JP2002520260A (ja) 2002-07-09

Similar Documents

Publication Publication Date Title
CA2336781C (en) Hypericin and hypericum extract: specific t-type calcium channel blocker, and their use as t-type calcium channel targeted therapeutics
US7195783B2 (en) Hypericin and hypericum extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics
Lam et al. Relaxant effects of danshen aqueous extract and its constituent danshensu on rat coronary artery are mediated by inhibition of calcium channels
US10376529B2 (en) Combination of pentacyclic triterpenes and hydroxytyrosol and derivatives thereof
US9629786B2 (en) Monoterpene derivatives of chalcone or dihydrochalcone and their use as depigmenting agents
KR102461853B1 (ko) 식물 기원의 다원 행동 생물학적 활성 물질
Moghadam et al. Metabolite profiling for caffeic acid oligomers in Satureja biflora
Sánchez-Recillas et al. Airway smooth muscle relaxant activity of Cordia dodecandra A. DC. mainly by cAMP increase and calcium channel blockade
Jeong et al. Inhibitory constituents of Euonymus alatus leaves and twigs on nitric oxide production in BV2 microglia cells
KR101449796B1 (ko) 헤디치움 코로나리움 유래 랍단 디터펜 화합물 및 이의 용도
Qiu et al. Sesquiterpenoids from the fruits of Alpinia oxyphylla Miq. and their neuroprotective effect
KR20010052636A (ko) 하이페리쿰 퍼포라툼의 추출물 및 그를 함유한 제제
KR102422492B1 (ko) 카나비제롤 유도체
EP2970090B1 (de) Neuartige antineurodegenerative naturstoffe aus fructus alpiniae oxyphyllae und gesamtsynthese davon
CN113735814B (zh) 桃金娘酮类化合物及其在制备抗流感病毒药物中的应用
US9884836B2 (en) 2-substituted-5-hydroxy-4H-chromen-4-ones as novel ligands for the serotonin receptor 2B (5-HT2B)
WO2002078685A1 (fr) Medicaments pour une lesion vasculaire
Opletalová et al. Synthesis and biological evaluation of (E)-3-(nitrophenyl)-1-(pyrazin-2-yl) prop-2-en-1-ones
Deiva et al. 2-furyl (phenyl) methanol isolated from Atractilis gummifera rhizome exhibits anti-leishmanial activity
EP0233105B1 (de) Therapeutische Zusammenstellungen auf Basis von 3-Alkoxyflavonen und Derivate von 3-Alkoxyflavonen
Lee et al. Isolation and characterization of sesquiterpenes from Arecophila saccharicola YMJ96022401 with NO production inhibitory activity
KR100291524B1 (ko) 신경세포 보호활성을 가지는 신나메이트 유도체
JP2003171349A (ja) 新規なジテルペン類、及びこれを用いた組成物、抗炎症剤、抗癌剤
CN110204477B (zh) 一种具有抗氧化作用的二萜生物碱及其在制备药物中的应用
JP4077723B2 (ja) クライネチンおよびその誘導体、調製方法および使用

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted